Olema Pharmaceuticals reported higher third-quarter losses as it expanded spending on late-stage breast-cancer trials and prepared for the possible commercialization of its lead drug, palazestrant. The clinical-stage company ended September with $413.8 million in cash, cash equivalents and marketable securities.
Its main near-term catalyst is top-line data from the pivotal Phase 3 OPERA-01 trial, expected in the first quarter of 2027. Olema also reported continued enrollment in a second pivotal palazestrant trial and advanced development plans for OP-3136, a KAT6 inhibitor.
Key details
-
OPERA-01 data are expected in early 2027. The trial is evaluating palazestrant in second- and third-line metastatic breast cancer. Olema said it remains on track to report top-line results in the first quarter of 2027.
-
Enrollment is continuing in OPERA-02. This pivotal Phase 3 trial is studying palazestrant with ribociclib in first-line metastatic breast cancer. Olema said enrollment is accelerating; its view that the combination could become a new standard of care is management’s assessment, not a trial result.
-
Olema is advancing OP-3136 in multiple settings. The company plans to begin enrolling patients in a Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026, in collaboration with Bayer.
-
Several study updates are scheduled for December. Olema plans to present data at the San Antonio Breast Cancer Symposium from studies of OP-3136 with fulvestrant, palazestrant with everolimus, and palazestrant with atirmociclib. The studies involve patients with advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.
-
The company appointed Jason O’Byrne as chief financial officer. Olema said he joined during the quarter and brings experience in corporate strategy, capital markets, and financial management and operations.
-
Net loss widened to $73.6 million, from $42.2 million in the third quarter of 2025. Olema attributed the increase to greater trial enrollment and development activity, manufacturing and clinical-supply work, early commercialization preparations for palazestrant, and higher personnel costs.
-
Research and development expenses rose to $67.6 million from $40.0 million. The increase reflected spending on OPERA-01 and OPERA-02, manufacturing and supply for those programs, continued advancement of OP-3136, and higher personnel costs. Non-cash stock-based compensation within R&D was $7.7 million, compared with $2.6 million a year earlier. Excluding that compensation, non-GAAP R&D expenses were $59.9 million, versus $37.4 million.
-
General and administrative expenses increased to $9.9 million from $5.9 million. Olema linked the rise to investment in personnel and corporate infrastructure for its expanding late-stage development program and preparations for potential commercialization.
Olema also planned to present preclinical research on selective degradation of KAT6A in estrogen receptor-positive breast cancer at a November cancer-research symposium.
Plain-English implications
The quarter’s higher spending reflects a larger late-stage clinical program and preparations for a possible move toward commercialization. The $413.8 million cash and securities balance provides a snapshot of available funds, but the reported results do not specify how long that balance is expected to last.